Form 4 for TEVA TEVA PHARMACEUTICAL INDUSTRIES LTD
Accepted 2025-11-18 00:00:00 ET · period of report 2025-11-14 · accession 0001193125-25-286134 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-11-18 | 2025-11-14 | TEVA | Fox Christine | EVP, Head of U.S. Commercial | S - Sale | $25.11 | -30.0K | 28.4K | -51% | -$753.3K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Ordinary Shares | 2025-11-14 | S | D | 30,000 | $25.11 | 28,384 | D | — | — | (F1) The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. |